|
Originally published In Press as doi:10.1074/jbc.M110883200 on January 28, 2002
J. Biol. Chem., Vol. 277, Issue 14, 11987-11994, April 5, 2002
The Clostridium ramosum IgA Proteinase Represents a
Novel Type of Metalloendopeptidase*
Klaudia
Kosowska §¶,
Jesper
Reinholdt ,
Lone Kjær
Rasmussen**,
Artur
Sabat§,
Jan
Potempa§,
Mogens
Kilian , and
Knud
Poulsen 
From the Department of Medical Microbiology and
Immunology, Department of Oral Biology, and
** Department of Molecular and Structural Biology, University
of Aarhus, Aarhus C DK-8000, Denmark and the § Department of
Microbiology and Immunology, Institute of Molecular Biology and
Biotechnology, Jagiellonian University, Krakow 30-387, Poland
Received for publication, November 13, 2001, and in revised form, January 14, 2002
 |
ABSTRACT |
Clostridium ramosum is part of the
normal flora in the human intestine. Some strains produce an IgA
proteinase that specifically cleaves human IgA1 and the IgA2m(1)
allotype. This prolylendopeptidase was purified from a broth culture
supernatant, and N-terminal sequences of the native protein and tryptic
fragments thereof were determined. A fragment of the iga
gene encoding the IgA proteinase was isolated using degenerate primers
in PCR, and the complete gene was obtained by inverse PCR. The identity
of the iga gene was confirmed by heterologous expression in
Escherichia coli. The deduced amino acid sequence indicated
a signal peptide of 30 residues and a secreted proteinase of 133,828 Da. A typical Gram-positive cell wall anchor motif was identified in
the C terminus. The presence of a putative zinc-binding motif
His-Glu-Phe-Gly-His together with inhibition studies indicate that the
proteinase belongs to the zinc-dependent
metalloproteinases. However, the sequence of the C. ramosum
IgA proteinase shows no overall similarity to other proteins except for
significant identity around the zinc-binding motif with family
M6 of metalloendopeptidases, and the unique sequence of the IgA
proteinase in this area presumably establishes a new subfamily.
The GC percentage of the iga gene is significantly higher than that for the entire genome of C. ramosum,
suggesting that the gene was acquired recently in evolution.
 |
INTRODUCTION |
IgA is the major class of immunoglobulin in human mucosal
secretions. Two subclasses, IgA1 and IgA2, exist, and IgA2 is found in
three allelic forms, A2m(1), IgA2m(2), and A2m(3), among which IgA2m(1)
is expressed mainly in Caucasians (1). The IgA1 subclass is predominant
in the upper respiratory tract and in serum, whereas more even
proportions of IgA1 and IgA2 occur in intestinal and urogenital
secretions (2, 3). A number of bacterial species that colonize mucosal
membranes of man produce IgA1 proteinase. This group of postproline
endopeptidases cleaves one of several Pro-Ser or Pro-Thr peptide bonds
in the hinge region of human IgA1, including its secretory form,
S-IgA1, within an inserted stretch of 13 amino acid residues lacking in
IgA2. IgA1 proteinase-producing species include the three leading
causes of bacterial meningitis, Neisseria meningitidis,
Hemophilus influenzae, and Streptococcus pneumoniae; three commensal streptococci, Streptococcus
mitis, Streptococcus oralis, and Streptococcus
sanguis; Gemella hemolysans; and several species of
Capnocytophaga and Prevotella. In addition, the
urogenital pathogens Neisseria gonorrhoeae and
Ureaplasma urealyticum produce IgA1 proteinase (reviewed in
Refs. 4 and 5).
It is conceivable that IgA1 proteinases enable the bacterial species to
escape specific immune defense on mucosal surfaces, although lack of
relevant animal models has precluded definitive identification of their
exact biological significance (5). Notably, human IgA1 cleaving
activity among these bacteria has evolved in at least three independent
evolutionary lineages, emphasizing the biological importance of these
enzymes. Inhibition studies and molecular characterizations have shown
that the Hemophilus and Neisseria IgA1
proteinases are homologous serine-type proteinases, the streptococcal
IgA1 proteinases are mutually related metalloendopeptidases, and the
enzyme from Prevotella melaninogenica (formerly
Bacteroides melaninogenicus) is a cysteine proteinase
(reviewed in Ref. 5). An IgA1 proteinase of N. gonorrhoeae
has been shown to cleave not only human IgA1 but also LAMP1
(lysosome-associated membrane protein 1) and tumor necrosis factor (TNF ) receptor II, features that may contribute to the pathogenesis
of infections caused by these bacteria (6, 7).
Clostridium ramosum is a strict anaerobic, Gram-positive,
spore-forming bacterium. It is part of the commensal flora in the human
intestine (8, 9), and only rarely has it been associated with disease
(10). Some strains of C. ramosum produce an IgA proteinase
that cleaves human IgA1 and IgA2 allotype A2m(1) at a Pro-Val peptide
bond at positions 221-222 just N-terminal to the hinge region (8, 11,
12). In IgA2m(2) and IgA2m(3), the Pro at position 221 is substituted
by Arg, apparently rendering these allotypes resistant to cleavage by
the IgA proteinase. Other Clostridium species may produce
proteinase(s) with similar activity (13). The C. ramosum IgA
proteinase is inhibited by high concentrations of EDTA, suggesting that
it is a metalloproteinase (11). Otherwise, this enzyme has not yet been characterized.
Here we describe the purification, cloning, and characterization of the
C. ramosum IgA proteinase. Analysis of the deduced translation product of the iga gene encoding the enzyme
revealed that it is a metalloendopeptidase with a putative extended
zinc-binding motif
HEXXHXXXGXXD.
The primary structure of the IgA proteinase shows no significant
overall similarity to any other known metalloendopeptidase, including
any IgA1 proteinase belonging to this class of proteolytic enzymes.
Notably, however, the sequence of 30 residues around the zinc-binding
motif shows up to 60% identity to the equivalent region of proteinases
grouped into the family M6 of metallopeptidases, including PrtV
proteinase of Vibrio cholerae and immune inhibitor A of
Bacillus thuringiensis. The GC% of the
iga gene is significantly higher than that reported for the
C. ramosum genome, suggesting that the IgA proteinase gene
was acquired recently in evolution through horizontal gene transfer.
 |
EXPERIMENTAL PROCEDURES |
Bacterial Strains--
C. ramosum strain AK183, which
produces an IgA proteinase that cleaves both human IgA1 and the
IgA2m(1) allotype, was obtained from Dr. Y. Fujiyama (Kyoto, Japan).
Bacteria were grown anaerobically at 37 °C in 2× YT medium (14)
supplemented with 0.05% sodium thioglycolate. The 2× YT medium was
used because it is devoid of high molecular weight proteins that may
complicate subsequent purification of the proteinase. Escherichia
coli JM 109 (Stratagene, La Jolla, CA) was used as host for
propagation of recombinant forms of plasmid pUC19. E. coli
One Shot was used for cloning derivatives of the pCR-TOPO vector
(Invitrogen, Groningen, The Netherlands), and E. coli
BL21(DE3)pLysS (R & D Systems Europe, Abingdon, UK) was used for the
expression cloning. The E. coli strains were grown in 2× YT
or LB medium (14) supplemented with antibiotics when appropriate.
Preparation of the IgA Proteinase--
The cell-free supernatant
of a 5-liter culture of C. ramosum was obtained by
centrifugation (6,000 × g, 30 min, 4 °C). Solid (NH4)2SO4 was added stepwise to
47% saturation, which in a pilot experiment was found to precipitate
the IgA proteinase, and NaN3 was added to a final
concentration of 0.05%. The precipitate formed overnight at 4 °C
was collected by centrifugation (6,000 × g, 45 min,
4 °C), dissolved in 0.05 M Tris-HCl, pH 8.2 (buffer T), dialyzed against the same buffer, and stored at 20 °C until used. The ammonium sulfate cut was further fractionated by size exclusion chromatography on a column (1.6 × 50 cm) of Sepharose 12 (prep grade; Amersham Biosciences) equilibrated in buffer T. Eluent fractions
containing the IgA proteinase were identified by the capacity to cleave
human IgA1 (see below). Fractions with maximal IgA1 cleaving activity
were pooled and subjected to anion exchange chromatography on a Mono-Q
column (Amersham Biosciences) equilibrated with buffer T. Protein
fractions eluted with a gradient of NaCl (0-1 M) in buffer
T were analyzed for IgA1 cleaving activity.
IgA Proteinase Activity Assays--
IgA proteinase activity was
detected by its capacity to cleave purified human myeloma IgA1.
Briefly, IgA proteinase test samples were incubated with myeloma IgA1
at 0.5 mg ml 1 in buffer T at 37 °C overnight, and
cleavage was subsequently detected by the presence of characteristic Fc
and Fd fragments as revealed by SDS-PAGE (15). This assay was used to
determine the susceptibility of the recombinant IgA proteinase to
inhibition by human 2-macroglobulin and various
synthetic compounds including specific inhibitors of serine peptidases
(phenylmethylsulfonyl fluoride, 3,4-dichloroisocoumarin, and Pefabloc),
cysteine peptidases (E-64 and iodoacetamide), and metallopeptidases
(EDTA, 1,10-phenanthroline, phosphoramidon,
2-(N-hydroxycarboxamido)4-methyl
pentanoyl-L-Ala-Gly-NH2 (Zincov),
N-benzyloxycarbonyl-Pro-Leu-Glu-hydroxamate, and
p-aminobenzoyl-Gly-Pro-D-Leu-D-Ala-hydroxamic). Pefabloc was purchased from Roche Molecular Biochemicals, Zincov was
from Merck, 1,7-phenanthroline was from GFS Chemicals (Powell, OH), and
the other compounds were from Sigma. The
2-macroglobulin was titrated on trypsin prior to
use and found to be 60% active, and incubation time before adding IgA1
substrate was up to 5 h.
For quantitative purposes, IgA proteinase activity was titrated using a
previously described assay involving enzyme-linked immunosorbent assay
technology (16). Briefly, serial dilutions of test sample were
incubated with an equal volume of myeloma IgA1 substrate (50 µg
ml 1), after which reaction mixtures were incubated in
enzyme-linked immunosorbent assay wells precoated with antibody
specific for Fc . Subsequently, wells were incubated with
enzyme-conjugated antibody to immunoglobulin light chains and developed
with chromogenic substrate. In this assay, cleavage of IgA1 was
reflected as a decrease in OD signal relative to the signal measured
for wells receiving IgA1 incubated without protease. Based on a
regression curve fitted to a plot of OD against dilution, the IgA1
proteinase titer was calculated as the sample dilution corresponding to
a 50% decrease in OD.
To examine the effect of reducing agents on enzyme activity, purified
IgA proteinase was incubated with dithiothreitol (1 mM) or
-mercaptoethanol (1 mM) for 1 h at room
temperature, and the activities of such treated proteinases were
titrated along with an untreated control sample of the enzyme. To
prevent interference of reducing agents with the enzyme-linked
immunosorbent assay, reaction mixtures were diluted 1:15 with
phosphate-buffered saline prior to analysis.
To evaluate potential proteolytic activity of the IgA proteinase
against other substrates, several proteins at 1 mg ml 1
were incubated in a volume of 50 µl at 37 °C for 24 h with an amount of the partially purified recombinant proteinase capable of
cleaving completely 0.5 mg of human IgA1 within 2 h. The proteins used were human IgG, IgD, IgE, IgM, 2-macroglobulin,
1-proteinase, 1-antichymotrypsin (all
from Athens Research and Technology, Athens, GA) and fibrinogen, bovine
albumin, carboxymethylated lysozyme, collagen type I and IV, oxidized
insulin -chain, and gelatin from Sigma. After incubation, the
reaction was stopped by boiling in reducing sample buffer, and the
integrity of the proteins was analyzed by SDS-PAGE.
Amino Acid Sequencing--
The most active fractions eluted from
the Mono-Q column were subjected to reducing SDS-PAGE, blotted onto
ProBlott membranes (PerkinElmer Life Sciences), and stained with
Coomassie Blue. The band corresponding to the presumed IgA proteinase
was excised, and the N-terminal sequence was determined using an ABI
477A/120A protein sequencer (PerkinElmer Life Sciences). For generation of tryptic peptides, the band in the polyacrylamide gel stained with
Coomassie Blue was excised from several lanes and digested in
situ as described (17). In brief, after washing with a mixture of
ammonium bicarbonate and acetonitrile, pieces of the gel were shrunk
with acetonitrile and dried completely. A solution containing modified
trypsin (Promega, Madison, WI) was allowed to soak into the gel pieces.
After incubation overnight at 37 °C, generated peptides were
recovered by extraction and separated by narrow bore RP-HPLC using the
SMART system (Amersham Biosciences). Amino acid sequencing of selected
peptides was performed as described above.
Southern Blot Analysis--
Unless otherwise stated, the DNA
manipulations were performed according to Sambrook et al.
(14). Whole-cell DNA from C. ramosum was isolated, digested
with EcoRI, and subjected to agarose gel electrophoresis and
Southern blot analysis including hybridization at high and low
stringency as described previously (18). As probes we used a 5.1-kb
fragment of the S. sanguis strain ATCC 10556 iga
gene (18) and a PCR product of genomic DNA from C. ramosum strain AK183 amplified with the primers
5'-AACGTGTTTTCGGGCAGATGA-3' and 5'-TGATAGTCTTGCATCGCTTTC-3', identified
in the present study, using the Expand Long Template PCR System as
recommended by the supplier (Roche Molecular Biochemicals). The DNA
probes were purified after agarose gel electrophoresis (QIAEX II Gel
Extraction Kit, Qiagen, Valencia, CA) and labeled with
[32P]dCTP (Random Labeling Kit, Roche Molecular Biochemicals).
Sequencing the IgA Proteinase Gene--
Several degenerate
primers with sequences corresponding to reverse translation of the
obtained amino acid sequences of the peptides analyzed were purchased
from DNA Technology (Aarhus, Denmark). The primers were combined in
pairs of a forward and a reverse one and used in PCRs containing 100 ng
of genomic DNA and 30 pmol of each primer using Ready To Go PCR beads
(Amersham Pharmacia Biotech) and subjected to the following cycling
parameters for 30 cycles: 94 °C for 1 min, 55 °C for 1 min,
72 °C for 2 min, with an initial denaturation step at 94 °C for 5 min and a final extension at 72 °C for 8 min. The resulting PCR
products were cloned into the E. coli plasmid vector
pCR-TOPO using the TOPO-TA Cloning KIT (Invitrogen). For inverse PCR,
the genomic DNA was digested with either MspI or
EcoRI, and 50 ng of the resulting fragments was circularized
in a 20-µl reaction volume (Rapid DNA Ligation Kit; Roche Molecular
Biochemicals). The self-ligated mixture was purified with Wizard
Minicolumns (Promega) and used as template in the inverse PCR with
primers pointing outwards using either Ready To Go PCR beads or the
Expand High Fidelity PCR System (Roche Molecular Biochemicals) and the
same cycling parameters as described above except that the annealing
temperature was 60 °C. The inverse PCR products were cloned into
E. coli plasmids pCR-TOPO or pUC19. The ExoIII/S1 Deletion
Kit (MBI, Fermentas, Lithuania) was used for construction of plasmid
clones with nested, unidirectional deletions for sequencing the insert
of recombinant plasmids using the universal M13 primers.
Plasmid DNAs for sequencing were prepared as recommended by the
supplier of the sequencing kit, and PCR products were purified with
Wizard Minicolumns (Promega). Individual sequence reactions on plasmid
DNA were performed with the Taq DyeDeoxy-Terminator cycle
sequencing Kit (PerkinElmer Life Sciences), whereas Thermo Sequenase
Dye Terminator Cycle Sequencing Kit (Amersham Biosciences) was used for
sequencing PCR products. Sequence reactions were analyzed with an ABI
PRISM 377 DNA sequencer (PerkinElmer Life Sciences). As sequencing
primers, we used the universal M13 sequencing primers as well as
oligonucleotides designed on the basis of preceding sequences. The DNA
sequence was determined for both strands of the iga gene.
Computer analysis of the sequences was performed with programs included
in the GCG package (Genetics Computer Group, Madison, WI). BLAST and
PSI-BLAST at NCBI (available on the World Wide Web at
www.ncbi.nlm.nih.gov/BLAST/) were used for data base searching.
Expression of the
ORF1--
For expression in
E. coli of the ORF, we used the vector pGEX-5T, which is
designed to express a recombinant fusion protein consisting of a
histidine hexapeptide and glutathione S-transferase followed
by the amino acid sequence of interest (19). The primers 5'-CCGATGACCATTGGATCCGCATCAAAGC-3' and
5'-GCTTAAAGGTCTATTCTCGAGTTATTCAGCG-3' were used in a PCR on
genomic DNA from strain AK183 to amplify a fragment encoding the
presumed secreted form of the IgA proteinase, and, in addition, the
primers add a BamHI and an XhoI restriction site,
respectively. For the PCR, we used the Pwo polymerase
as recommended by the supplier (Roche Molecular Biochemicals). The vector and the PCR product were digested with BamHI and
XhoI, ligated, and transformed into E. coli
JM109. Colonies harboring the correct recombinant plasmid, termed
pGEX-5T-iga, were identified by restriction analysis of plasmid DNA.
The plasmid DNA was subsequently used to transform E. coli
BL21(DE3)pLysS, and expression of the recombinant protein was induced
in a culture with an A600 of 0.6 by adding IPTG
to a final concentration of 1 mM. After an additional 4 h of growth, the cells were pelleted, resuspended in
phosphate-buffered saline, pH 7.3, and disrupted by mild sonication.
The supernatant of the lysate was tested for IgA1 cleaving activity as
described above.
The recombinant IgA proteinase was partially purified using affinity
chromatography on glutathione-Sepharose (Amersham Pharmacia Biotech).
Briefly, the E. coli cells from 3 liters of culture grown
for 4 h at 25 °C after induction of expression by IPTG were suspended in 50 ml of phosphate-buffered saline and disrupted using a
French press. Cell debris was removed by ultracentrifugation (105,000 × g for 60 min), and recombinant IgA
proteinase was separated using an on-column cleavage and purification
procedure as recommended by the manufacturer. Thrombin was removed
using benzamidine-Sepharose (Amersham Biosciences).
Site-directed Mutagenesis--
Three mutants of the C. ramosum IgA proteinase, H539A, D550A, and E551A, were generated.
Mutator oligonucleotide primers were designed to introduce restriction
enzyme sites to facilitate subsequent screening for mutated DNA products.
For the H539A mutation, the codon CAC for histidine was replaced by
GCC, a codon for alanine. In addition, a silent mutation in
codon Ala538 was introduced by changing GCA into GCG,
creating an Eco52I restriction site, CGGCCG. Outward facing
primers for the H539A mutagenesis were
5'-AACCGTGTCCAAACTCGGCCGCAAAAGTTT-3' and 5'-TGCTCGGTCTCGGTGATGAATA-3'. For the D550A mutation, the codon GAT for aspartic acid was replaced by
GCT, a codon for alanine. In addition, a silent mutation in codon
Gly549 was introduced by changing GGT into GGG,
creating an Eco88I restriction site, CTCGGG. Outward facing
primers for the D550A mutagenesis were
5'-ATCCGTTACTGTATTCAGCCCCGAGACCGA-3' and
5'-ATTTGCTTGACGATAAGGAACTTAA-3'. For the E551A mutation, the codon GAA
for glutamic acid was replaced by GCA, a codon for alanine. This change
created an Mph1103I restriction site, ATGCAT. Outward facing
primers for the E551A mutagenesis were
5'-CAAATATCCGTTACTGTATGCATCACCGAG-3' and
5'-CTTGACGATAAGGAACTTAAATCAC-3'. A 1.2-kb
SalI-HindIII fragment of plasmid pGEX-5T-iga was
cloned into HindIII- and SalI-digested pTZ19R,
generating pSH1200. Desired mutations and restriction sites were
introduced into pSH1200 by inverse PCR using Pfu polymerase
as recommended by the supplier (Fermentas) and the primer pairs
described above. Following temperature cycling, the PCR products were
treated with DpnI restriction endonuclease to digest
parental DNA template methylated by the Dam methylase. After heat
inactivation of DpnI, the DNAs were used to transform E. coli JM109 supercompetent cells. The mutants were
selected by restriction analysis of plasmid DNA and confirmed by
sequence analysis. The 1.2-kb SalI-HindIII
fragments with desired mutations were cloned into SalI- and
HindIII-restricted pGEX-5T-iga. The resulting plasmids,
termed pGEX-iga-H539A, pGEX-iga-D550A, and pGEX-iga-E551A, had single
amino acid substitutions at amino acids His539 to Ala,
Asp550 to Ala, and Glu551 to Ala, respectively.
The plasmids were transformed into E. coli BL21(DE3)pLysS,
and expression of recombinant proteins was induced as described above.
 |
RESULTS AND DISCUSSION |
Purification, Characterization, and Amino Acid Sequence Analysis of
the C. ramosum IgA Proteinase--
Differences in the proportion of
secreted compared with cell-associated forms of the IgA1 proteinase
produced have been observed for different species and strains of
bacteria (20). Here we found that in the early stationary phase the
majority of the IgA1 cleaving activity in C. ramosum strain
AK183 was secreted into the medium (data not shown). The C. ramosum IgA proteinase was purified from culture supernatant by a
combination of ammonium sulfate precipitation, size exclusion, and
anion exchange chromatography. Eluent fractions containing the
proteinase were identified by their ability to cleave human IgA1,
releasing intact Fc and Fd fragments (analyzed by SDS-PAGE), and the
activity in fractions was determined by titration of the ability to
cleave human IgA1 (analyzed by the enzyme-linked immunosorbent
assay-based assay). The titer of IgA proteinase activity in the initial
5 liters of culture supernatant was 8, and in the peak activity
fraction (0.5 ml) upon anion exchange it was 128. This modest increase
in activity suggested a loss of enzyme activity during the process of
purification. Because C. ramosum is a strictly anaerobic
bacterium, we speculated that the enzyme might regain its activity if
subjected to reducing conditions. However, we found that preincubation
with neither 1 mM -mercaptoethanol nor 1 mM
dithiothreitol had any influence on its capacity to cleave human IgA1.
The loss of activity during purification remains unexplained.
The IgA proteinase was active at neutral pH, and it retained activity
upon storage at 20 °C for several weeks. It has been previously
shown that 100 mM EDTA inhibits the activity of the C. ramosum IgA proteinase (11). We found that the IgA1
cleaving activity was completely inhibited by 0.5 mM EDTA,
suggesting that the enzyme is a metalloproteinase. More detailed
enzymatic characterization of the IgA proteinase activity was performed
using the partially purified recombinant form of the enzyme (see below).
Reducing SDS-PAGE analysis of the Mono-Q fractions revealed that the
intensity of a band corresponding to a protein of 130 kDa correlated
with the IgA1 proteinase activity, suggesting that this band
represented the IgA proteinase (Fig. 1).
The 130-kDa protein as well as tryptic peptides derived from it and
purified by HPLC were subjected to N-terminal amino acid sequence
analysis. The N-terminal sequence of the 130-kDa protein was determined to be AXKPDIKVXDYVKMGVYNN, while the N-terminal
sequences EYGFHYFISPSD, FEDGXEIPNTAGG, and EYTGAY were
obtained for three of the tryptic peptides. None of the sequences
shared significant similarity to other bacterial IgA1 proteinases or to
any known proteins, as revealed by searching the GenBankTM
data base.

View larger version (91K):
[in this window]
[in a new window]
|
Fig. 1.
IgA proteinase activity correlates with
presence of a 130-kDa protein. Every second fraction upon anion
exchange was subjected to SDS-PAGE and stained with Coomassie Blue. The
figure shows the fractions eluted with 0.3-1.0
M NaCl. The titer of human IgA1 cleaving activity is
indicated below each lane. Mobilities
of molecular mass markers (in kDa) are indicated to the
right.
|
|
The iga Gene Sequence from C. ramosum Strain AK183--
Although
the molecular mass and catalytic mechanism of the C. ramosum
IgA proteinase was similar to that of the IgA1 proteinase from
streptococcal species (18, 21-23), the C. ramosum iga gene encoding the IgA proteinase showed no homology to the streptococcal iga genes. Even when using hybridization at very low
stringency conditions, genomic DNA from C. ramosum strain
AK183 did not hybridize with the iga gene from S. sanguis in a Southern blot analysis (data not shown). To isolate
the C. ramosum iga gene, the N-terminal amino acid sequences
obtained for the putative IgA proteinase and the tryptic fragments of
it were used to design degenerate primers for PCR amplification of a
part of the C. ramosum iga gene using genomic DNA from
strain AK183 as template. Forward primer 5'-ATGGGIGTITAYAAYAAY-3' was
deduced from reverse translation of the amino acid sequence MGVYNN from
the N-terminal sequence of the mature protein, and reverse primer
5'-RAARTARTGRAAICCRTAYTC-3' was deduced from the sequence EYGFHYF
obtained for one of the tryptic peptides. A single amplicon of ~1.2
kb was produced. The nucleotide sequence of this fragment was
determined and used for design of primers for inverse PCR to obtain the
complete iga gene sequence. Combined, a sequence of 4242 nucleotides was determined. To correct for errors that may occur due to
imperfect fidelity of the DNA polymerases in the PCRs and which would
be carried over in the cloning procedures applied in the sequencing
strategy (see "Experimental Procedures"), the sequence obtained was
used to design primers for PCR amplification of overlapping fragments of the AK183 iga gene. Direct sequencing of the amplicons
revealed a total of five errors in the initial sequence.
The sequence contained a large ORF with the potential of
encoding a protein of 1,234 amino acids. The N-terminal sequence of the
130-kDa protein as well as the N-terminal sequences of the tryptic
fragments of it were all identified within the primary structure
deduced from the ORF (Fig. 2). The ORF
was preceded by typical promoter elements (Fig. 2). The sequence
GGAAGT, six nucleotides upstream of the proposed ATG start codon, is
similar to the Shine and Dalgarno sequence GGAGGT (24) and is in a
suitable position for a ribosome binding site (25). Thirty-five
nucleotides upstream of the proposed ATG start codon, the sequences
TATAATA and TTGAC separated by 17 nucleotides match the 10 and 35
promoter elements, respectively (26, 27). Another possible ATG start codon was located 15 nucleotides downstream of the first one. A
possible transcriptional terminator in the form of an inverted repeat structure was identified downstream of the ORF (Fig.
2).

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide sequence of the iga
gene from C. ramosum strain AK183. The
deduced amino acid sequence of the large ORF is shown below
the gene sequence. The proposed 35 and 10 promoter sequences and
the Shine-Dalgarno sequence are underlined. The inverted
repeat structure downstream of the ORF is shown by divergent
arrows. The cleavage site for the N-terminal signal peptide
is indicated by an arrow. The putative zinc-binding motif is
shown by triangles below the sequence,
and the obtained N-terminal amino acid sequences are
underlined and shown in boldface type.
|
|
A Southern blot analysis of genomic DNA of C. ramosum AK183
restricted with PstI, which has no recognition sites in the
iga gene sequence determined, and hybridized with a 4-kb
fragment containing the ORF showed a single band of 14 kb (results not shown), suggesting that the iga gene is a single copy gene
in C. ramosum strain AK183.
Interestingly, the GC percentage of the iga gene was
43 compared with an overall GC percentage of 26 in the C. ramosum genome (28). This difference strongly suggests that the
IgA proteinase gene in C. ramosum was acquired recently in
evolution through horizontal gene transfer from another bacterium with
a higher GC percentage.
Expression of the IgA Proteinase in E. coli and Characterization of
the Recombinant Protein--
To verify that the ORF in fact
represented the C. ramosum iga gene, we performed
heterologous expression in E. coli. The sequence encoding
the presumed mature IgA proteinase (positions 537-4151 in Fig. 2) was
amplified by PCR and cloned into the E. coli expression vector pGEX-5T. This vector is designed to express a recombinant fusion
protein consisting of a histidine hexapeptide and glutathione S-transferase followed by the amino acid sequence of
interest. The plasmid construct, termed pGEX-5T-iga, was transformed
into E. coli BL21(DE3)pLysS. Intracellular expression of the
fusion protein was induced by IPTG, and after incubation the cells were disrupted by sonication. The resulting lysate showed IgA proteinase activity (Fig. 3), demonstrating that the
ORF sequenced was the iga gene. In addition, N-terminal
sequencing of the Fc fragment generated by the recombinant fusion
protein revealed the sequence VPSTP. This sequence is identical to that
previously reported for Fc induced by the C. ramosum IgA
proteinase (11), indicating that the specificity of the recombinant
proteinase was identical to the native one.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 3.
Heterologous expression in E. coli
of the C. ramosum IgA proteinase. Lysates
of E. coli strains induced with IPTG were incubated with or
without human IgA1 and analyzed by SDS-PAGE followed by staining with
Coomassie Blue. Lane 1, molecular mass markers in
kDa; lane 2, lysate of E. coli
BL21(DE3)pLysS transformed with the vector pGEX-5T; lane
3, E. coli BL21(DE3)pLysS transformed with
pGEX-5T and incubated with IgA1; lane 4, E. coli BL21(DE3)pLysS transformed with pGEX-5T-iga; lane
5, E. coli BL21(DE3)pLysS transformed with
pGEX-5T-iga and incubated with IgA1; lane 6,
intact IgA1 incubated with buffer. Positions of intact IgA1 heavy
chain, light chain, and the proteolytic fragments Fc and Fd are
indicated to the right.
|
|
Relatively high expression of the active recombinant form of the IgA
proteinase enabled us to perform a more detailed characterization of
the enzyme activity. First, we confirmed that the IgA proteinase is
highly specific for human IgA, since none of the other human immunoglobulins, including IgG, IgD, IgE, and IgM, were susceptible to
cleavage. In addition, none of the other proteins tested (fibrinogen, albumin, collagen type I and IV, and two serpins,
1-proteinase and 1-antichymotrypsin) were
cleaved by the IgA proteinase even after incubation for 24 h at an
enzyme concentration sufficient to cleave 0.5 mg of human IgA1 in
2 h (data not shown). Especially significant was the lack of an
effect on serpins, since this group of proteins possess a
surface-exposed loop (the reactive site loop), which is readily cleaved
even by nontarget proteinases with a restricted specificity like
periodontain (29) and collagenase (30). These data, together with the
lack of activity against unstructured polypeptides such as gelatin,
carboxymethylated lysozyme (Fig. 4), and
oxidized insulin -chain, indicate an exquisite specificity of the
C. ramosum IgA proteinase. Such a narrow specificity limited
to the hinge region of the IgA molecule is also a common feature of
other IgA1 proteinases (4, 5).

View larger version (86K):
[in this window]
[in a new window]
|
Fig. 4.
Lack of degradation of carboxymethylated
lysozyme, gelatin, and fibrinogen by the recombinant IgA
proteinase. Carboxymethylated lysozyme (lanes
1 and 2), gelatin (lanes 3 and 4), and fibrinogen (lanes 5 and
6) were incubated overnight alone (lanes
1, 3, and 5) or with the recombinant
IgA proteinase partially purified on glutathione-Sepharose
(lanes 2, 4, and 6) and
analyzed by SDS-PAGE. Molecular mass standards are shown in
lane 7. The gel was loaded with 5, 10, and 3 µg
of lysozyme, gelatin, or fibrinogen, respectively, and the amount of
IgA proteinase added was sufficient to cleave 5 µg of human IgA1 in
2 h.
|
|
It has been assumed that the C. ramosum IgA proteinase is a
metalloproteinase solely on the basis of its inhibition by EDTA (11).
To extend enzyme characterization, we investigated the effect of a
broad range of class-selective inhibitors of serine proteinases,
cysteine proteinases, and metalloproteinases on the activity of the
partially purified recombinant IgA proteinase. At 1 mM
concentration, none of the compounds specific for the first two groups
of peptidases, including phenylmethylsulfonyl fluoride,
3,4-dichloroisocoumarin, Pefabloc, E-64, and iodoacetamide, had any
effect on IgA1 cleavage (results not shown). Also, among several
metalloproteinase inhibitors tested, only metal-chelating compounds,
1,10-phenanthroline and EDTA, inhibited the enzyme activity (Fig.
5, lanes 3 and
4). Significantly, a nonchelating isomer of phenanthroline
(1,7-phenanthroline) had no effect (Fig. 5, lane
8). Neither phosphoramidon nor Zincov, a compound
specifically designed to inhibit metalloproteinases, had any effect on
IgA1 cleavage (Fig. 5, lanes 5 and 6).
The IgA proteinase activity was also insensitive to inhibition by other
hydroxamate-based compounds such as
N-benzyloxycarbonyl-Pro-Leu-Glu-hydroxamate (Fig. 5,
lane 7) and
p-aminobenzoyl-Gly-Pro-D-Leu-D-Ala-hydroxamic acid as well as 2-macroglobulin (results not shown).
Taken together, the inhibition profile of the C. ramosum IgA
metalloproteinase reiterates the unique character of the enzyme.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
Inhibition of IgA cleaving activity of the
recombinant C. ramosum IgA proteinase by
metallopeptidase inhibitors. Recombinant IgA proteinase partially
purified on glutathione-Sepharose was preincubated alone
(lane 2) or with 1 mM
1,10-phenanthroline (lane 3), 0.5 mM
EDTA (lane 4), 50 mM phosphoramidon
(lane 5), 0.1 mM Zincov
(lane 6), 1.0 mM
N-benzyloxycarbonyl-Pro-Leu-Glu-hydroxamate (lane
7), or 10 mM 1,7-phenanthroline (lane
8) for 30 min before human IgA1 was added. The mixtures were
then incubated for an additional 2 h at 37 °C. The reactions
were stopped by boiling in reducing sample buffer and analyzed by
SDS-PAGE. The intact IgA1 control incubated with buffer is shown in
lane 1.
|
|
The Amino Acid Sequence of the C. ramosum IgA Proteinase--
The
deduced amino acid sequence of this novel proteinase, when compared
with the N-terminal sequence determined for the secreted protein,
indicates that the first 30 amino acids of the primary translation
product comprise the signal peptide. This is in perfect agreement with
the predictions made on the basis of the primary structure inferred
from the iga gene sequence by the computer program SignalP
(31). Taking the signal peptide into account, the deduced mature IgA
proteinase contains 1,204 amino acids, has a calculated
Mr of 133,828, and has an isoelectric point of 5.79. This is in agreement with the size of the purified proteinase observed in SDS-PAGE (130 kDa).
In the C terminus, we identified a putative cell wall sorting signal
that in other Gram-positive bacteria has been found to target surface
proteins to the cell wall (32). The sequence SPQTG at positions
1196-1200 presumably constitutes the sortase recognition site. It was
previously reported that in Clostridium difficile the
sortase appears to recognize SPXTG or PPXTG
instead of the conventional LPXTG motif (33). In the
C. ramosum IgA proteinase, a small spacer, DNSN, separated
this motif from a transmembrane domain, IFLWFALLFVSAAGVTGITAY, followed
by a positively charged tail, NKKKKEHAE, at the C terminus. These
features are in agreement with other presumed substrates for
sortase-like proteins (33). Provided that the anchor motif is
functional, the sortase cleaves at the Thr-Glu peptide bond in the
recognition site and covalently links the threonine, and thereby the
N-terminal part of the protein, to peptidoglycan in the cell wall (32,
34). However, we found that the majority of IgA proteinase activity in
C. ramosum AK183 was released into the medium. Release of
surface proteins with a typical Gram-positive cell wall anchor motif
has been reported for the and antigens present in the c protein complex of Streptococcus agalactiae (35-37), and
Streptococcus mutans sheds surface antigen P1 and secretes
exo- -D-fructosidase (38, 39). The release of anchored
surface proteins may be brought about by turnover of the peptidoglycan
layer or by proteolytic cleavage of the proteins next to the anchoring.
Provided that the cell wall anchor sorting signal in the C. ramosum IgA proteinase is functional, the mechanism by which the
proteinase is released from the cell wall remains to be elucidated.
A putative zinc-binding motif was identified at positions 539-543
followed by an aspartic acid residue seven positions downstream in the
sequence
HEXXHXXXGXXD
and resembling the extended zinc-binding site typical for the metzincin
group of metallopeptidases, but as a significant difference in the IgA proteinase there are four instead of three residues between the second
His and Gly (40, 41). In all members of this clan with the exception of
leishmanolysins, the third zinc ligand is His or Asp, located
invariably six residues downstream of the
HEXXH motif (42). In case of C. ramosum IgA proteinase, there are seven residues separating the
second (His) and the third (Asp) zinc ligand. Nevertheless, the
sequence encompassing the zinc-binding motif is remarkably similar to
that of the PrtV proteinase of V. cholerae and the immune
inhibitor A of B. thuringiensis (Fig. 6), each of which is a proteolytic member
of clan MA. This significant similarity includes the presence of the
conserved Gly, which allows the formation of the -turn necessary to
bring the zinc ligands together in this group of metalloproteinases
(43, 44). Therefore, it can be predicted that His539,
His543, and Asp550 of the C. ramosum
IgA proteinase polypeptide chain form the metal binding site, while
Glu540 is the active site residue.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 6.
Conserved region in C. ramosum
IgA proteinase. A comparison is shown of the region
around the predicted active site and zinc-binding domains (indicated by
A and Z, respectively) of C. ramosum
IgA proteinase (IgAPrt), B. thuringiensis immune
inhibitor A (InA; accession number X55436), and V. cholerae PrtV (PrtV; accession number Y00557), with a
hypothetical secreted proteinase of S. coelicolor
(ScPprt; accession number CAB51001) and those of
PrtV-related proteinases obtained from the conceptual translation of
sequences retrieved from genome data bases (available on the World Wide
Web at www.ncbi.nlm.nih.gov/Microb_blast/unfinishedgenome.html): BaPrt1
from B. anthracis, BaPrt2 from B. anthracis,
BstePrt from B. stearothermophilus, ClaPrt from C. acetobutylicum, and SputPrt from S. putrefaciens. The
sequences were aligned using the ClustalW multiple sequence alignment
tool. The arrows above the sequences
indicate Gly and Met residues conserved in the metzincin family of
metallopeptidases. The asterisks indicate identical
residues, and dots indicate conserved residues with similar
properties in members of the M6 family of metzincins. Gaps
(dashes) have been introduced to optimize alignment. The
numbers of the first and last amino acid in the alignment are indicated
for each protein.
|
|
To experimentally verify the prediction that His539 and
Asp550 constitute part of the zinc binding motif and are
therefore indispensable for the enzyme activity, we constructed and
expressed mutant forms of the IgA proteinase in which these residues
were individually replaced by alanine. As expected, neither of these
two mutants possessed IgA1 cleaving activity (Fig.
7, lanes 4 and
5). Notably, however, the E551A mutant was fully
active (Fig. 7, lane 6). These data corroborate
the alignment-based predictions of the zinc-binding and catalytic
residues (Fig. 6) and indicate that the IgA proteinase of C. ramosum can be included into clan MA. The endopeptidases from clan
MA are also known as metzincins, because there is a conserved Met in a
turn that underlines the active site (41, 45). However, this Met is
absent in the IgA proteinase, indicating the uniqueness of this enzyme,
which most likely establishes a new subfamily of metallopeptidases in
family M6 of clan MA.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 7.
IgA cleaving activity of the recombinant
wild-type IgA proteinase and mutants with putative residues involved in
zinc binding and catalytic activity replaced by alanine. Lysates
of E. coli BL21(DE3)pLysS transformed with pGEX-5T-iga
(lane 3), pGEX-5T-iga-H539A (lane
4), pGEX-5T-iga-D550A (lane 5),
pGEX-5T-iga-E551A (lane 6), or pGEX-5T vector
(lane 7) induced with IPTG were incubated with
human IgA1 and analyzed by SDS-PAGE. Molecular mass standards are shown
in lane 1, and IgA1 incubated with buffer is
shown in lane 2. In this assay compared with
Figs. 3 and 5 we used a different preparation of human IgA1 with a
distinct glycosylation, and therefore the fragments migrate slightly
differently in the gel. Below the SDS-PAGE gel, a Western
blot analysis of appropriate lysates probed with anti-His6
antibodies demonstrates that the lack of IgA1 cleaving activity was not
due to deficiency in expression of the mutated proteinase. The position
of the recombinant proteinase is indicated by an
arrow.
|
|
Currently, the family M6 consists of only three members listed in the
MEROPS Data Base (available on the World Wide Web at www.merops.co.uk)
exemplified by PrtV proteinase of V. cholerae and immune
inhibitor A of B. thuringiensis. A PSI-BLAST search in the
unfinished genomes, using these proteinase sequences for comparison,
revealed, however, that similar putative proteinases are encoded in the
genomes of Bacillus stearothermophilus, Streptomyces coelicolor, Clostridium acetobutylicum,
Shewanella putrefaciens, and Bacillus anthracis
(Fig. 6). The latter species can potentially express at least four
different metalloproteinases that are homologous, with one being almost
identical to immune inhibitor A (94% identity in the primary
structure), the only member of the M6 family with defined biological
function. This metalloendopeptidase cleaves the antibacterial proteins
attacin and cecropin found in insects, disabling the immune system of
lepidoptera infected by B. thuringiensis (46, 47). In this
respect, it is interesting to note that the IgA proteinase has an
analogous function, since its activity is also specifically aimed at
the host antimicrobial defense mechanisms.
The importance of IgA1 cleavage by mucosal pathogens or commensals in
their ability to escape immune defense seems apparent but is difficult
to establish due to the lack of a relevant animal model (5). The
biological significance of IgA1 proteinase activity can, however, be
inferred indirectly from the fact that nature developed these specific
proteinases based on three different catalytic mechanisms. Moreover, it
is now apparent that within the metalloproteinase class, the
specificity to cleave human IgA is present in two evolutionary
lineages, with the C. ramosum enzyme capable of cleaving
both IgA1 and IgA2m(1) molecules. This seems to be a major advantage
for this bacterium, because in the gut environment, a natural habitat
of C. ramosum, both isotypes of IgA occur in comparable
amounts. It remains to be examined whether strains of C. ramosum producing this proteinase preferentially colonize subjects
homozygous for the IgA2m(1) allotype. Besides, the expression of the
recombinant IgA proteinase facilitates production of a large amount of
the active, recombinant protein in a pure form for further studies of
this intriguing molecule.
 |
ACKNOWLEDGEMENTS |
We thank Allan Shaw for the kind help and
fruitful discussions. Mark Pallen is acknowledged for help in defining
the cell wall anchor motif. The technical help of Lise Hald is greatly acknowledged.
 |
FOOTNOTES |
*
This work was supported by Danish Medical Research Council
Grant 9702265; the Committee for Scientific Research, KBN, Poland, Grant 6 PO4A 06418 (to J. P. and K. K.); and the Velux Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AY028440.
¶
Recipient of a fellowship from the Socrates-Erasmus Foundation.

To whom correspondence should be addressed: Dept. of Medical
Microbiology and Immunology, Bartholin Bldg., University of Aarhus, Aarhus C DK-8000, Denmark. Tel.: 45-89421736; Fax: 45-86196128; E-mail:
kp@microbiology.au.dk.
Published, JBC Papers in Press, January 28, 2002, DOI 10.1074/jbc.M110883200
 |
ABBREVIATIONS |
The abbreviations used are:
ORF, open reading
frame;
IPTG, isopropyl-1-thio- -D-galactopyranoside.
 |
REFERENCES |
| 1.
|
Mestecky, J.,
Moro, I,
and Underdown, B. J.
(1999)
in
Mucosal Immunology
(Ogra, P. L.
, Mestecky, J.
, Lamm, M. E.
, Strober, W.
, Bienenstock, J.
, and McGhee, J. R., eds), 2nd Ed.
, pp. 133-152, Academic Press, Inc., San Diego, CA
|
| 2.
|
Brandzaeg, P.,
and Farstad, I. N.
(1999)
in
Mucosal Immunology
(Ogra, P. L.
, Mestecky, J.
, Lamm, M. E.
, Strober, W.
, Bienenstock, J.
, and McGhee, J. R., eds), 2nd Ed.
, pp. 439-468, Academic Press, Inc., San Diego, CA
|
| 3.
|
Kirkeby, L.,
Rasmussen, T. T.,
Reinholdt, J.,
and Kilian, M.
(2000)
Clin. Diagn. Lab. Immunol.
7,
31-39[Medline]
[Order article via Infotrieve]
|
| 4.
|
Plaut, A. G.
(1983)
Annu. Rev. Microbiol.
37,
603-622[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kilian, M.,
Reinholdt, J.,
Lomholt, H.,
Poulsen, K.,
and Frandsen, E. V. G.
(1996)
Acta Pathol. Microbiol. Immunol. Scand.
104,
321-338
|
| 6.
|
Lin, L,
Ayala, P.,
Larson, J.,
Mulks, M.,
Fukuda, M.,
Carlsson, S. R.,
Enns, C.,
and So, M.
(1997)
Mol. Microbiol.
24,
1083-1094[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Beck, S. C.,
and Meyer, T. F.
(2000)
FEBS Lett.
472,
287-292[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Senda, S.,
Fujiyama, Y.,
Ushijima, T.,
Hodohara, K.,
Bamba, T.,
Hosoda, S.,
and Kobayashi, K.
(1985)
Microbiol. Immunol.
29,
1019-1028[Medline]
[Order article via Infotrieve]
|
| 9.
|
Stark, P. L.,
and Lee, A.
(1982)
J. Pediatr.
100,
362-365[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Brook, I.
(1995)
J. Med. Microbiol.
42,
78-82[Abstract/Free Full Text]
|
| 11.
|
Fujiyama, Y.,
Kobayashi, K.,
Senda, S.,
Benno, Y.,
Bamba, T.,
and Hosoda, S.
(1985)
J. Immunol.
134,
573-576[Abstract]
|
| 12.
|
Fujiyama, Y.,
Iwaki, M.,
Hodohara, K.,
Hosoda, S.,
and Kobayashi, K.
(1986)
Mol. Immunol.
23,
147-150[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Hashim, O. H.,
and Hassan, H.
(1991)
Immunology
73,
235-238[Medline]
[Order article via Infotrieve]
|
| 14.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 15.
|
Reinholdt, J.,
Tomana, M.,
Mortensen, S. B.,
and Kilian, M.
(1990)
Infect. Immun.
58,
1186-1194[Abstract/Free Full Text]
|
| 16.
|
Reinholdt, J.
(1996)
J. Immunol. Methods
191,
39-48[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Hellman, U.
(1997)
in
Protein Structure Analysis: Preparation, Characterization, and Microsequencing
(Kamp, R. M.
, Choli-Papadopoulu, T.
, and Wittmann-Liebold, B., eds)
, pp. 97-104, Springer-Verlag, Heidelberg, Germany
|
| 18.
|
Poulsen, K.,
Reinholdt, J.,
and Kilian, M.
(1996)
Infect. Immun.
64,
3957-3966[Abstract]
|
| 19.
|
Berthold, H.,
Frorath, B.,
Scanarini, M.,
Abney, C. C.,
Ernst, B.,
and Northemann, W.
(1992)
Biotechnol. Lett.
14,
245-250[CrossRef]
|
| 20.
|
Reinholdt, J.,
and Kilian, M.
(1997)
Infect. Immun.
65,
4452-4459[Abstract]
|
| 21.
|
Gilbert, J. V.,
Plaut, A. G.,
and Wright, A.
(1991)
Infect. Immun.
59,
7-17[Abstract/Free Full Text]
|
| 22.
|
Poulsen, K.,
Reinholdt, J.,
Jespersgaard, C.,
Boye, K.,
Brown, T. A.,
Hauge, M.,
and Kilian, M.
(1998)
Infect. Immun.
66,
181-190[Abstract/Free Full Text]
|
| 23.
|
Wani, J. H.,
Gilbert, J. V.,
Plaut, A. G.,
and Weiser, J. N.
(1996)
Infect. Immun.
64,
3967-3974[Abstract]
|
| 24.
|
Shine, J.,
and Dalgarno, L.
(1974)
Proc. Natl. Acad. Sci. U. S. A.
71,
1342-1346[Abstract/Free Full Text]
|
| 25.
|
Stormo, G. D.,
Schneider, T. D.,
and Gold, L. M.
(1982)
Nucleic Acids Res.
10,
2971-2996[Abstract/Free Full Text]
|
| 26.
|
Hawley, D. K.,
and McClure, W. R.
(1983)
Nucleic Acids Res.
11,
2237-2255[Abstract/Free Full Text]
|
| 27.
|
Gentz, R.,
and Bujard, H.
(1985)
J. Bacteriol.
164,
70-77[Abstract/Free Full Text]
|
| 28.
|
Johnson, J. L.,
and Francis, B. S.
(1975)
J. Gen. Microbiol.
88,
229-244[Abstract/Free Full Text]
|
| 29.
|
Nelson, D.,
Potempa, J.,
Kordula, T.,
and Travis, J.
(1999)
J. Biol. Chem.
274,
12245-12251[Abstract/Free Full Text]
|
| 30.
|
Mast, A. E.,
Enghild, J. J.,
Nagase, H.,
Suzuki, K.,
Pizzo, S. V.,
and Salvesen, G.
(1991)
J. Biol. Chem.
266,
15810-15816[Abstract/Free Full Text]
|
| 31.
|
Nielsen, H.,
Engelbrecht, J.,
Brunak, S.,
and von Heijne, G.
(1997)
Protein Eng.
10,
1-6[Abstract/Free Full Text]
|
| 32.
|
Navarre, W. W.,
and Schneewind, O.
(1999)
Microbiol. Mol. Biol. Rev.
63,
174-229[Abstract/Free Full Text]
|
| 33.
|
Pallen, M. J.,
Lam, A. C.,
Antonio, M.,
and Dunbar, K.
(2001)
Trends Microbiol.
9,
97-101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Schneewind, O.,
Fowler, A.,
and Faull, K. F.
(1995)
Science
268,
103-106[Abstract/Free Full Text]
|
| 35.
|
Jerlstrom, P. G.,
Chhatwal, G. S.,
and Timmis, K. N.
(1991)
Mol. Microbiol.
5,
843-849[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Bevanger, L.,
and Iversen, O.-J.
(1983)
Acta Pathol. Microbiol. Scand. Sect. B
91,
75-81
|
| 37.
|
Michel, J. L.,
Madoff, L. C.,
Olson, K.,
Kling, D. E.,
Kasper, D. L.,
and Ausubel, F. M.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10060-10064[Abstract/Free Full Text]
|
| 38.
|
Lee, S. F.
(1992)
Infect. Immun.
60,
4032-4039[Abstract/Free Full Text]
|
| 39.
|
Burne, R. A.,
Schilling, K.,
Bowen, W. H.,
and Yasbin, R. E.
(1987)
J. Bacteriol.
169,
4507-4517[Abstract/Free Full Text]
|
| 40.
|
Hooper, N. M.
(1994)
FEBS Lett.
354,
1-6[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Stocker, W.,
Grams, F.,
Baumann, U.,
Reinemer, P.,
Gomis-Ruth, F. X.,
McKay, D. B.,
and Bode, W.
(1995)
Protein Sci.
4,
823-840[Medline]
[Order article via Infotrieve]
|
| 42.
|
Barrett, A. J.,
Rewlings, N. D.,
and Woessner, J. F.
(1998)
Handbook of Proteolytic Enzymes
, pp. 1130-1132, Academic Press, London
|
| 43.
|
Gomis-Ruth, F. X.,
Stocker, W.,
Huber, R.,
Zwilling, R.,
and Bode, W.
(1993)
J. Mol. Biol.
229,
945-968[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Gomis-Ruth, F. X.,
Kress, L. F.,
Kellermann, J.,
Mayr, I.,
Lee, X.,
Huber, R.,
and Bode, W.
(1994)
J. Mol. Biol.
239,
513-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Bode, W.,
Gomis-Ruth, F. X.,
and Stockler, W.
(1993)
FEBS Lett.
331,
134-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Dalhammar, G.,
and Steiner, H.
(1984)
Eur. J. Biochem.
139,
247-252[Medline]
[Order article via Infotrieve]
|
| 47.
|
Lovgren, A.,
Zhang, M.,
Engstrom, A.,
Dalhammar, G.,
and Landen, R.
(1990)
Mol. Microbiol.
4,
2137-2146[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Takenouchi-Ohkubo, L. M. Mortensen, K. R. Drasbek, M. Kilian, and K. Poulsen
Horizontal transfer of the immunoglobulin A1 protease gene (iga) from Streptococcus to Gemella haemolysans
Microbiology,
July 1, 2006;
152(7):
2171 - 2180.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. W. Senior and J. M. Woof
Effect of Mutations in the Human Immunoglobulin A1 (IgA1) Hinge on Its Susceptibility to Cleavage by Diverse Bacterial IgA1 Proteases
Infect. Immun.,
March 1, 2005;
73(3):
1515 - 1522.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|